A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 2085-2094

  Guo, Xiao Fang ^a   Zhu, Xiao Fei ^a   Shang, Yue ^a   Zhang, Sheng Hua ^a   Zhen, Yong Su ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; ENEDIYNE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; LIDAMYCIN; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENEDIYNES; FEMALE; HUMANS; LIGANDS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGOPEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950686367     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2699     Document Type: Article

References (36)

1. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167
3. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibody and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-457
4. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-489
5. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization parterner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655
6. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
7. Hynes NE, Lane HA. ErbB receptors and cancer: the complexicity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354
8. Kokai Y, Myers JN, Wada T, et al. Synergistic interaction of p185cneu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989;58:287-292
9. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003;54:343-369
10. Medinger M, Drevs J. Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 2005;11:1139-1149
11. Takai N, Jain A, Kawamata N, et al. 2C4, a monoclonal antibody against HER2, disrupt the HER signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-2708
12. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumorderived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
13. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-237
14. Frankel AE, Woo JH. Bispecific immunotoxins. Leuk Res 2009;33:1173-1174
15. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008;99:1415-1425
16. van de Poll ML, van vugt MJ, Lenferink AE, van Zoelen EJ. Indentification of the minimal requirement for binding to the human epidermal growth factor (EGF) receptor using chimeras of human EGF and EGF repeat of Drosophila Notch. J Biol Chem 1998;273:16075-16081
17. Shirai H, Kidera A, Nakamura H. H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett 1999;455:188-197
18. Kuroda D, Shirai H, Kobori M, Nakamura H. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins 2008;73:608-620
19. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007;25:921-929
20. Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem 2008;8:123-131
21. Rathore D, Nayak SK, Batra JK. Expression of ribonucleolytic toxin restrictocin in Escherichia coli: purification and characterization. FEBS Lett 1996;392:259-262
22. Miao QF, Liu XY, Shang BY, Ouyang ZG, Zhen YS. An enediyneenergized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs 2007;18:127-137
23. Schier R, McCall A, Adams PA, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996;263:551-567
24. Schier R, Bye J, Apell G, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J mol Biol 1996;255:28-43.
25. Stish BJ, Chen H, Shu YQ, Panoskaltsis-Mortari A, Vallera DA. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 2007;13:6486-6493
26. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895
27. Stish BJ, Chen H, Shu YQ, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007;13:3058-3067
28. Bera TK, Onda M, Brinkmann U, Pastan I. A bivalent disulfidestabilized Fv with improved antigen binding to erbB2. J Mol Biol 1998;281:475-483
29. Friedman M, Lindstrom S, Ekerljung L, et al. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem 2009;54:121-131
30. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B cell leukemia/lymphoma. Clin Cancer Res 2005;11:3879-3888
31. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004;17:157-164
32. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639
33. Schmidt M, Hynes NE, Groner B, Wels W. A bivalent single-chain antidody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 1996;65:538-546
34. Heimbrook DC, Stirdivant SM, Ahern JD, et al. Transforming growth factor α-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc Natl Acad Sci U S A 1990;87:4697-4701
35. Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989;49:3482-3488
36. Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 2003;63:1834-1837